Biohaven EBITDA Margin 2016-2023 | BHVN

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Biohaven (BHVN) over the last 10 years. The current EBITDA margin for Biohaven as of March 31, 2023 is .
Biohaven EBITDA Margin Historical Data
2021-06-30 $0.16B $-0.17B -111.61%
2021-03-31 $0.07B $-0.17B -230.56%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.414B $0.463B
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $135.883B 8.30
GSK (GSK) United Kingdom $69.205B 9.66
Bio-Rad Laboratories (BIO.B) United States $11.071B 29.60
QIAGEN (QGEN) Netherlands $10.425B 22.01
Ginkgo Bioworks Holdings (DNA) United States $3.504B 0.00
Arcus Biosciences (RCUS) United States $1.484B 0.00
Emergent Biosolutions (EBS) United States $0.414B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.183B 0.00
Enzo Biochem (ENZ) United States $0.109B 0.00
SQZ Biotechnologies (SQZ) United States $0.017B 0.00